GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » Raia Drogasil SA (BSP:RADL3) » Definitions » EBIT

Raia Drogasil (BSP:RADL3) EBIT : R$2,026 Mil (TTM As of Mar. 2024)


View and export this data going back to 1995. Start your Free Trial

What is Raia Drogasil EBIT?

Raia Drogasil's earnings before interest and taxes (EBIT) for the three months ended in Mar. 2024 was R$495 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Mar. 2024 was R$2,026 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Raia Drogasil's annualized ROC % for the quarter that ended in Mar. 2024 was 10.22%. Raia Drogasil's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2024 was 18.97%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Raia Drogasil's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2024 was 3.83%.


Raia Drogasil EBIT Historical Data

The historical data trend for Raia Drogasil's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Raia Drogasil EBIT Chart

Raia Drogasil Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1,062.86 879.25 1,273.75 1,705.17 1,908.31

Raia Drogasil Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 390.30 587.00 469.56 473.97 495.11

Competitive Comparison of Raia Drogasil's EBIT

For the Pharmaceutical Retailers subindustry, Raia Drogasil's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Raia Drogasil's EV-to-EBIT Distribution in the Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, Raia Drogasil's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Raia Drogasil's EV-to-EBIT falls into.



Raia Drogasil EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was R$2,026 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Raia Drogasil  (BSP:RADL3) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Raia Drogasil's annualized ROC % for the quarter that ended in Mar. 2024 is calculated as:

ROC % (Q: Mar. 2024 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Dec. 2023 ) + Invested Capital (Q: Mar. 2024 ))/ count )
=2100.172 * ( 1 - 30.98% )/( (14189.991 + 14185.056)/ 2 )
=1449.5387144/14187.5235
=10.22 %

where

Invested Capital(Q: Dec. 2023 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=20094.412 - 5492.1 - ( 412.321 - max(0, 8079.497 - 11561.674+412.321))
=14189.991

Invested Capital(Q: Mar. 2024 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=20651.653 - 6054.001 - ( 412.596 - max(0, 8386.386 - 12028.255+412.596))
=14185.056

Note: The Operating Income data used here is four times the quarterly (Mar. 2024) data.

2. Joel Greenblatt's definition of Return on Capital:

Raia Drogasil's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2024 is calculated as:

ROC (Joel Greenblatt) %(Q: Mar. 2024 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Dec. 2023  Q: Mar. 2024
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=1980.456/( ( (5937.687 + max(4487.471, 0)) + (6081.235 + max(4377.273, 0)) )/ 2 )
=1980.456/( ( 10425.158 + 10458.508 )/ 2 )
=1980.456/10441.833
=18.97 %

where Working Capital is:

Working Capital(Q: Dec. 2023 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(3084.94 + 7197.427 + 821.533) - (5492.1 + 0 + 1124.329)
=4487.471

Working Capital(Q: Mar. 2024 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(2963.924 + 7677.322 + 927.225) - (6054.001 + 0 + 1137.197)
=4377.273

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Mar. 2024) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Raia Drogasil's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Mar. 2024 )
=2025.641/52947.937
=3.83 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Raia Drogasil EBIT Related Terms

Thank you for viewing the detailed overview of Raia Drogasil's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


Raia Drogasil (BSP:RADL3) Business Description

Traded in Other Exchanges
Address
Avenue Corifeu de Azevedo Marques, 3097 Butanta, Sao Paulo, SP, BRA, 05339-9000
Raia Drogasil SA is a large retail drug store operator in Brazil. The company's stores sell branded and generic medication, over-the-counter medicine, health and beauty aids, perfumery, cosmetics, household items, and personal care products. The company also acts as a pharmacy benefit manager, performing medical purchases with prenegotiated discounts. The majority of Raia Drogasil's revenue is generated through branded drug sales, while the bulk of the remaining revenue stems from perfumery, over-the-counter drugs, and generic drugs. The company owns a variety of stakes in operational subsidiaries.

Raia Drogasil (BSP:RADL3) Headlines

No Headlines